Alzheimer’s disease (AD) causes gradual cognitive decline and dementia. Until recently, the definitive diagnosis of AD was based on autopsy assessments of brain amyloid-β plaques and tau neurofibrillary tangles, the defining biological features of AD.
Biomarkers of amyloid-β and tau are vital for measuring AD pathology in living people and for differentiating between different neurodegenerative diseases. With the latest progress in AD research, accurate in-vivo diagnosis of AD is becoming increasingly crucial.
In this video Joseph Therriault, PhD discusses the AD biomarkers and their use in clinical and research settings and explore future research areas for wider clinical practice use.
Joseph Therriault, PhD, McGill Centre for Studies in Aging. Faculty of Medicine, McGill University, Montréal, Québec, Canada.
Related content
The pathology of ischaemic stroke is complex, but commonly involves the formation of a clot that travels in the blood to or within the brain and becomes lodged in the blood vessels of the brain (a thromboembolism), which can reduce or block blood flow (an occlusion).
Post-stroke fatigue is an under-recognized NPS, which healthcare professionals should anticipate in patients.
Emotional lability describes episodes of involuntary and uncontrollable crying and/or laughing, outside of socially appropriate circumstances and when it is incongruent with the patient’s emotional state.